Neuland Laboratories Limited — Q4 FY25 earnings call

Call held 15 May 2025

Management summary

Neuland Labs reported a weak Q4, concluding a year of consolidation (FY25) with a slight revenue decline attributed to product life cycles. Management characterized FY25 performance as expected and emphasized the inherent volatility of their business, urging investors to take a 3-year block view. The outlook for FY26 is optimistic, with growth expected to resume driven by the commercialization of new CMS molecules and the operationalization of the new production block at Unit 3. However, management remained highly cautious, refusing to provide any quantitative guidance on revenue or margins, citing business confidentiality and variability.

Highlights

  • Q4 FY25 total income stood at ₹335.8 crores, a decrease of 14% YoY from ₹390.4 crores.

  • Q4 FY25 EBITDA was ₹58.2 crores with a margin of 17.3%, a sharp decline from ₹112.2 crores in Q4 FY24.

  • Q4 FY25 Profit After Tax was ₹27.7 crores, compared to ₹67.6 crores in the previous year.

  • FY25 full-year total income saw a marginal degrowth of 4.7% to ₹1,497.3 crores.

  • FY25 full-year EBITDA (excluding exceptional items) was ₹342.8 crores, down from ₹474.5 crores in FY24.

  • Generated strong free cash flow of ₹111 crores for the full year FY25.

  • Management expects a resumption of growth in FY26, using the higher FY24 revenue as the base for comparison.

  • A new CMS molecule is expected to be commercialized in FY26, adding to a molecule that was commercialized in FY25.

Concerns

  • Inherent business volatility and uneven revenue

Key financials

3 periods

Q4

  • Total Income
    ₹335.8 Cr
    YoY -14%
  • EBITDA
    ₹58.2 Cr
    YoY -48.1%
  • EBITDA Margin
    17.3%
  • PAT
    ₹27.7 Cr
    YoY -59%
  • EPS
    ₹21.6

FY25

  • Total Income
    ₹1,497.3 Cr
    YoY -4.7%
  • Free Cash Flow
    ₹111 Cr

FY25, ex-exceptional

  • EBITDA
    ₹342.8 Cr
    YoY -27.7%

What they filed

Q1 FY27: revenue up 119.1%, net profit up 950.0% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue311 398 328 293 514 +65%440 +11%776 +137%642 +119%
EBITDA61 86 51 34 155 +154%77 −10%307 +502%223 +556%
Net profit32 101 28 14 96 +200%40 −60%213 +661%147 +950%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • CMS (Custom Manufacturing Solutions)
    ₹637 Cr Revenue (FY25)

Guidance & targets

Growth

  • Overall Growth Trajectory Growth · FY26 · Medium confidence Resume growth on the FY24 base
    Therefore, we expect our growth trajectory to resume in FY26 on the FY24 base.

    — Saharsh Davuluri

Capacity

  • Unit 3 New Block Capacity · FY26 · High confidence Start commercial production
    The additional production block in Unit 3 has been capitalized, and we expect to start commercial production in FY26.

    — Abhijit Majumdar

Pipeline

  • New CMS Molecule Commercialization Pipeline · FY26 · High confidence 1 new molecule to be commercialized
    We also had a molecule which got commercialized during the year and expect another molecule to be commercialized in FY26.

    — Saharsh Davuluri

Margin

  • Margin Direction Margin · FY26 · Low confidence Margins going up
    So I think we would like to keep it a little vague, but definitely, you can see margins going up.

    — Saharsh Davuluri

Risks & concerns

  • Inherent business volatility and uneven revenue

    high

    Management repeatedly emphasized that the CDMO and specialty GDS business is lumpy, making quarter-on-quarter or even annual comparisons difficult.

    Management acknowledged

  • Lack of quantitative guidance

    medium

    The refusal to provide specific revenue or margin targets makes it difficult for investors to assess the magnitude of the expected FY26 recovery.

    Analyst acknowledged

  • Margin recovery uncertainty

    medium

    While margins are expected to improve from the 'suboptimal' FY25 levels, management has clearly stated that the peak FY24 margins are not a guaranteed target.

    Management acknowledged

  • Potential US Tariffs

    low

    Management has no clarity on this but believes any potential tariffs would likely be passed on to customers.

    Analyst downplayed

Areas of evasion (3)

  • Quantitative revenue growth targets
  • Specific margin range for FY26
  • Specific therapy area/name of new molecules

Q&A highlights

1 direct
FY26 growth outlook and margin expectations Partial
Yes. I think whatever we have seen in FY24, I think we had also indicated that those are highly optimized kind of margins, right?... We had always said that that's more like a North Star of our margins. We don't expect that to be like a basis or a benchmark.

Management sets a cautious tone on margins, indicating the peak margins of FY24 are aspirational and not a new baseline, despite expecting revenue recovery.

Asked by Shyam Srinivasan, Goldman Sachs

Details on the new CMS molecule launching in FY26 Partial
The first source is non-Indian source and Neuland is getting added as a second source... I think the reason for the excitement is also that it is a relatively high-volume product.

Reveals that a key growth driver for FY26 is a high-volume, second-source contract, which typically implies more stable, long-term revenue streams.

Asked by Vidit Shah, Spark Capital

Frustration over lack of specific guidance Direct
Yes. No, thank you. I definitely understand your frustration. And I think a lot of analysts, I know you're an individual investor, but even a lot of analysts struggle to model our business because of these reasons. The confidential nature of the business creates additional challenges for us.

Management directly acknowledges the difficulty analysts and investors face in modeling the company, confirming that the lack of guidance is a deliberate policy due to business structure.

Asked by Gyanprakash Yadav, Individual Investor

2 min read 5 chapters

Detailed narrative

FY25 Performance: A Year of Consolidation

Neuland Labs positioned FY25 as a year of consolidation, with total income declining by 4.7% to ₹1,497.3 crores. The fourth quarter was particularly weak, with revenue down 14% YoY to ₹335.8 crores and EBITDA margin contracting significantly to 17.3%. Management attributed the decline to the 'natural life cycle' of certain products that contributed in FY24 but not at the same level in FY25, stating this was an expected outcome. Despite the profit decline, the company generated a strong free cash flow of ₹111 crores for the year and ended with a net cash position of ₹29 crores.

FY26 Outlook: Growth to Resume from FY24 Base

Management expressed optimism for a growth recovery in FY26. They guided for the growth trajectory to resume based on the higher revenue of FY24, effectively bypassing the weaker FY25 performance. Key drivers include the new production block at Unit 3 starting commercial production, a molecule commercialized in FY25 beginning to contribute, and another new CMS molecule expected to be commercialized in FY26. Management anticipates that the CMS business will be the primary growth engine compared to the GDS segment.

CMS Business Gaining Momentum

The Custom Manufacturing Solutions (CMS) business recorded revenues of approximately ₹637 crores in FY25. Management highlighted a 'snowballing' effect in their CDMO business, driven by a growing reputation, focused business development, and favorable macro factors (geopolitical shifts). The company is seeing higher quality opportunities and has established expertise in niche areas like deuterated chemistry and peptides, with 10-15 peptide projects currently in the pipeline. The new molecule set for FY26 commercialization is a high-volume, second-source contract in the COPD segment, signaling a move towards larger, more stable projects.

Margin Trajectory and Guidance Policy

While expecting revenues to rebound, management was very cautious on margins. They described FY25 margins as 'suboptimal' and expect them to improve with operating leverage in FY26. However, they repeatedly warned that the highly favorable margins of FY24 were a 'North Star' and not a new baseline. This cautious stance is part of a broader policy of not providing quantitative guidance, which management acknowledged frustrates investors but is necessary due to the confidential and inherently volatile nature of their project-based business.

Capital Allocation and Investments

The company invested ₹26.4 crores in capital expenditure during the year, primarily towards the new production block in Unit 3 which is now capitalized. The focus on cash generation was evident, with working capital at 107 days of sales. Neuland also paid back ₹39.4 crores of term loan debt. The significant INR 300-350 crore capex announced previously for large-scale peptide manufacturing capabilities at Unit 1 is proceeding, underscoring the company's strategic focus on this high-growth area.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls